MYCENAX BIOTECH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.45 TWD | -0.23% |
|
-6.16% | +21.71% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,837 | 2,981 | 4,129 | 5,811 | 7,699 | 7,350 |
| Enterprise Value (EV) 1 | 2,554 | 2,751 | 4,035 | 6,269 | 7,315 | 7,409 |
| P/E ratio | -10.3 x | -13.4 x | 134 x | -62.1 x | -13.7 x | -10.7 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 13.4 x | 7.63 x | 6.21 x | 7.51 x | 10.5 x | 11.3 x |
| EV / Revenue | 12.1 x | 7.04 x | 6.06 x | 8.1 x | 9.99 x | 11.4 x |
| EV / EBITDA | -10.4 x | -22 x | 26.8 x | 141 x | -33.3 x | -21.9 x |
| EV / FCF | -11.4 x | -13.9 x | -49.1 x | -5.37 x | -11 x | -1,096 x |
| FCF Yield | -8.74% | -7.18% | -2.04% | -18.6% | -9.06% | -0.09% |
| Price to Book | 3.13 x | 2.71 x | 3.41 x | 3.05 x | 2.48 x | 3 x |
| Nbr of stocks (in thousands) | 109,955 | 127,955 | 128,238 | 153,334 | 205,306 | 205,886 |
| Reference price 2 | 25.80 | 23.30 | 32.20 | 37.90 | 37.50 | 35.70 |
| Announcement Date | 3/29/19 | 3/26/20 | 3/30/21 | 3/25/22 | 3/14/23 | 3/14/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 211.4 | 390.8 | 665.3 | 774.3 | 732.3 | 652.6 |
| EBITDA 1 | -244.6 | -124.9 | 150.8 | 44.33 | -219.7 | -338.3 |
| EBIT 1 | -322.5 | -230.3 | 35.4 | -85.33 | -445 | -602.1 |
| Operating Margin | -152.55% | -58.91% | 5.32% | -11.02% | -60.77% | -92.26% |
| Earnings before Tax (EBT) 1 | -285.8 | -230 | 27.97 | -87.52 | -462.8 | -684 |
| Net income 1 | -274.4 | -218.2 | 30.95 | -89.86 | -453.6 | -682.8 |
| Net margin | -129.8% | -55.82% | 4.65% | -11.61% | -61.95% | -104.63% |
| EPS 2 | -2.496 | -1.735 | 0.2400 | -0.6100 | -2.744 | -3.322 |
| Free Cash Flow 1 | -223.3 | -197.5 | -82.2 | -1,168 | -662.5 | -6.763 |
| FCF margin | -105.61% | -50.53% | -12.36% | -150.83% | -90.47% | -1.04% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/29/19 | 3/26/20 | 3/30/21 | 3/25/22 | 3/14/23 | 3/14/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q2 | 2022 Q3 | 2022 Q4 |
|---|---|---|---|
| Net sales 1 | - | 159.3 | 195.9 |
| EBITDA | - | - | - |
| EBIT 1 | - | -163.2 | -174.8 |
| Operating Margin | - | -102.47% | -89.23% |
| Earnings before Tax (EBT) 1 | - | -176.2 | -189.1 |
| Net income 1 | -116.4 | -173 | -182.5 |
| Net margin | - | -108.61% | -93.19% |
| EPS 2 | -0.7600 | -1.120 | -0.9800 |
| Dividend per Share | - | - | - |
| Announcement Date | 8/11/22 | 11/11/22 | 3/14/23 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 458 | - | 58.6 |
| Net Cash position 1 | 283 | 230 | 94.5 | - | 384 | - |
| Leverage (Debt/EBITDA) | - | - | - | 10.33 x | - | -0.1732 x |
| Free Cash Flow 1 | -223 | -197 | -82.2 | -1,168 | -662 | -6.76 |
| ROE (net income / shareholders' equity) | -26.8% | -21.7% | 2.68% | -5.76% | -18.1% | -24.6% |
| ROA (Net income/ Total Assets) | -16.6% | -11.4% | 1.4% | -2.18% | -7.33% | -9.15% |
| Assets 1 | 1,655 | 1,915 | 2,211 | 4,121 | 6,192 | 7,461 |
| Book Value Per Share 2 | 8.250 | 8.610 | 9.450 | 12.40 | 15.10 | 11.90 |
| Cash Flow per Share 2 | 1.960 | 1.510 | 2.270 | 1.870 | 6.450 | 2.520 |
| Capex 1 | 118 | 178 | 260 | 1,098 | 627 | 296 |
| Capex / Sales | 56.04% | 45.52% | 39.11% | 141.82% | 85.61% | 45.3% |
| Announcement Date | 3/29/19 | 3/26/20 | 3/30/21 | 3/25/22 | 3/14/23 | 3/14/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +21.71% | 275M | |
| -3.46% | 102B | |
| +1.41% | 96.29B | |
| +2.13% | 22.18B | |
| -15.84% | 21.2B | |
| -9.21% | 18.31B | |
| -39.98% | 17.38B | |
| -14.65% | 16.36B | |
| +4.39% | 13.97B | |
| +31.35% | 12.17B |
- Stock Market
- Equities
- 4726 Stock
- Financials Mycenax Biotech Inc.
